Anti-Hyperglycemic Effects of Refined Fractions from Cyclocarya Paliurus Leaves on Streptozotocin-Induced Diabetic Mice

To identify the chemical components responsible for the anti-hyperglycemic effect of Cyclocarya paliurus (Batal.) Iljinsk (Juglandaceae) leaves, an ethanol extract (CPE) and a water extract (CPW) of C. paliurus leaves, as well as their total flavonoids (CPF), triterpenoids (CPT) and crude polysaccharides (CPP), were prepared and assessed on streptozotocin (STZ)-induced diabetic mice. After being orally administrated once a day for 24 days, CPF (300 mg/kg), CPP (180 mg/kg), or CPF+CPP (300 mg/kg CPF + 180 mg/kg CPP) treatment reversed STZ-induced body weight and muscle mass losses. The glucose tolerance tests and insulin tolerance tests suggested that CPF, CPP, and CPF+CPP showed anti-hyperglycemic effect in STZ-induced diabetic mice. Furthermore, CPF enhances glucose-stimulated insulin secretion in MIN6 cells and insulin-stimulated glucose uptake in C2C12 myotubes. CPF and CPP suppressed inflammatory cytokine levels in STZ-induced diabetic mice. Additionally, CPF and CPP improved STZ-induced diabetic nephropathy assessed by H&E staining, blood urea nitrogen content, and urine creatinine level. The molecular networking and Emperor analysis results indicated that CPF showed potential anti-hyperglycemic effects, and HPLC–MS/MS analysis indicated that CPF contains 3 phenolic acids and 9 flavonoids. In contrast, CPT (650 mg/kg) and CPC (300 mg/kg CPF + 180 mg/kg CPP + 650 mg/kg CPT) did not show anti-hyperglycemic effect. Taken together, polysaccharides and flavonoids are responsible for the anti-hyperglycemic effect of C. paliurus leaves, and the clinical application of C. paliurus need to be refined.

Lecithin Inclusion by α-Cyclodextrin Activates SREBP2 Signaling in the Gut and Ameliorates Postprandial Hyperglycemia

Background: α-cyclodextrin (α-CD) is one of the dietary fibers that may have a beneficial effect on cholesterol and/or glucose metabolism, but its efficacy and mode of action remain unclear. Methods: In the present study, we examined the anti-hyperglycemic effect of α-CD after oral loading of glucose and liquid meal in mice. Results: Administration of 2 g/kg α-CD suppressed hyperglycemia after glucose loading, which was associated with increased glucagon-like peptide 1 (GLP-1) secretion and enhanced hepatic glucose sequestration. By contrast, 1 g/kg α-CD similarly suppressed hyperglycemia, but without increasing secretions of GLP-1 and insulin. Furthermore, oral α-CD administration disrupts lipid micelle formation through its inclusion of lecithin in the gut luminal fluid. Importantly, prior inclusion of α-CD with lecithin in vitro nullified the anti-hyperglycemic effect of α-CD in vivo, which was associated with increased intestinal mRNA expressions of SREBP2-target genes (Ldlr, Hmgcr, Pcsk9, and Srebp2). Conclusions: α-CD elicits its anti-hyperglycemic effect after glucose loading by inducing lecithin inclusion in the gut lumen and activating SREBP2, which is known to induce cholecystokinin secretion to suppress hepatic glucose production via a gut/brain/liver axis.

Anti-diabetic effect of Momordicacharantiaplant extract in streptozotocin induced diabetic mice

This study describes anti-hyperglycemic effect of Momordicacharantia extract commonly known as bitter melon. Random blood glucose levels were observed before and after plant extract administration. Powdered form of plant extract was used as an oral treatment. Diabetes was induced in animal (mice) models by using streptozotcin which is an artificial diabetes inducer. Maximum anti-hyperglycemic effect and blood glucose level reduction was observed in individual treatment of Momordicacharantiaextract (500mg/kg) which was 75% ± 1.3. This treatment was more effective as compared to Amaryl (3mg/kg) which shows effectiveness of 52% ± 2.4 and Glucophage (500mg/kg) which shows effectiveness of 29% ± 2.1. Results indicate that bitter melon contain anti-hyperglycemic proteins which are helpful in diabetes treatment without any toxic side effects. Still more research, experiments and testing needs to be perform. Keywords: Amaryl; Anti-hyperglycemic effect; Blood glucose levels; Body weight; Diabetes mellitus

A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders

Due to its anti-hyperglycemic effect, metformin is the first-line medication for the treatment of type 2 diabetes, particularly in people who are obese. However, metformin is a drug with a very wide range of pharmacological properties and reports of its therapeutic effect on diseases including inflammation and cancer are increasing. Numerous research groups have reported that metformin has beneficial effects on a variety of inflammatory skin disorders including psoriasis, acanthosis nigricans, acne, hidradenitis suppurativa, and allergic contact dermatitis. According to these reports, in addition to the well-known action of metformin, that is, its anti-hyperglycemic effect, NF-kB inhibition and the resulting alteration to the cytokine network may be the potential targets of metformin. Its anti-hyperandrogenism effect has also been confirmed as the major action of metformin in some inflammatory skin diseases. Moreover, novel regulatory mechanisms, including autophagy and antioxidant processes, have been suggested as promising mechanisms of action for metformin in inflammatory skin disorders.

Risk analysis of chewing betel quid among diabetic patients from the northeastern part of Bangladesh

BackgroundBetel quid (BQ) chewing is a common habit and a means of social interaction among the northeastern peoples of Bangladesh. Though this habit integrating in their daily life without knowing its toxic effect. Areca nut, which is one of the main components of BQ and may responsible for this addiction. Here, we assess to see how BQ chewing habit influence hyperglycemia among diabetic patients with respect to their lifestyle.MethodologyRandom blood sugar (RBS) test was evaluated from a total of 961 diabetic patients. Behavioral data associated with their daily lifestyle were collected from August 2018 to February 2019 from Sylhet Diabetic Hospital, Bangladesh. Student’s t-test, ANOVA and Fisher’s exact test were used to assess the RBS status between BQ chewer and non-chewer patients.ResultsHigher RBS was found in BQ chewer patients than non-chewer (mean ± SEM, 263.3 ± 4.768 vs. 251.0 ± 5.915mg/dl). Interestingly, it is significantly higher in raw areca nut user than dry nut (mean ± SEM, 278.0 ± 8.790 vs. 252.1 ± 6.835 mg/dl) only from BQ chewer group, suggesting that the habit of chewing raw nut may contribute to more hyperglycemic effect among diabetic patients. BQ habit enhances higher RBS level among smoker, non-smoker and patient’s having walking habit. In addition, BQ habit significantly influence to have high RBS in patients with family history with diabetes. Lack of awareness being diabetes have also been observed significantly in BQ chewer patients, while a higher level of RBS was seen in BQ group, who work in different sectors with sitting activities.ConclusionsDiabetic patients who chew betel quid are more prone to keep higher hyperglycemic. Utmost attention should be taken to discourage the use of BQ for proper management of diabetes control.